Skip to main content
Premium Trial:

Request an Annual Quote

FDA Grants EUAs for SARS-CoV-2 Tests, Kits From Exact Sciences, BioGx, Bio-Rad, Everlywell

NEW YORK — The US Food and Drug Administration this week granted separate Emergency Use Authorization for molecular SARS-CoV-2 tests from Exact Sciences and BioGx, an immunoassay for detecting the virus from Bio-Rad Laboratories, and an at-home specimen collection kit from Everlywell.

Exact's COVID-Flu Multiplex Assay is designed for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, and influenza B in anterior nasal swabs self-collected in a healthcare setting.

The RT-PCR-based test may also be used with anterior nasal swab specimens self-collected at home using the Exact Sciences Nasal Swab Home Collection Kit or the newly authorized Everlywell COVID-19 & Flu Test Home Collection Kit.

Exact's test may be performed only at the Madison, Wisconsin-based company's CLIA lab, according to the FDA. Everlywell's collection kit is only for use by CLIA labs designed by Everlywell.

The BioGx Xfree COVID-19 Direct RT-PCR assay is designed to detect SARS-CoV-2 nucleic acid in nasopharyngeal, anterior nasal, mid-turbinate, and oropharyngeal swab specimens, nasopharyngeal wash/aspirate, or nasal aspirates collected by a healthcare provider.

According to Birmingham, Alabama-based BioGx, patient samples can be added directly to a vial containing all RT-PCR reagents without the need for preprocessing or nucleic acid extraction.

It may be used by any lab CLIA-certified to perform high-complexity tests, the FDA said.

Bio-Rad's BioPlex 2200 SARS-CoV-2 IgG is designed for the qualitative and semi-quantitative detection of immunoglobulin G against SARS-CoV-2 in serum and plasma. The automated assay, which runs on the Hercules, California-based firm's BioPlex 2200 system, may be used by any lab CLIA-certified to perform moderate- or high-complexity tests.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.